Publication Name	World Journal of Gastroenterology
Manuscript ID	18550
Country	Japan

Received	2015-04-23 16:58
Peer-Review Started	2015-04-24 16:27
To Make the First Decision	2015-07-13 15:09
Return for Revision	2015-07-17 16:42
Revised	2015-07-26 10:12
Second Decision	2015-09-12 22:01
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-14 11:26
Articles in Press	2015-09-14 11:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-22 10:16
Publish the Manuscript Online	2015-10-19 09:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Evaluation and treatment of malignant ascites secondary to gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Hiromichi Maeda, Michiya Kobayashi and Junichi Sakamoto
Funding Agency and Grant Number	Funding Agency Grant Number Non-profit Epidemiological Research Organization
Corresponding Author	Junichi Sakamoto, MD, PhD, Tokai Central Hospital, Sohara Higashijima-cho, Kakamigahara, Gifu 504-8601, Japan. sakamjun@tokaihp.jp
Key Words	Ascites; Clinical benefit; Gastric cancer; Peritoneal dissemination; Paclitaxel
Core Tip	Malignant ascites affects approximately 10% of patients with gastric cancer (gc) and poses significant problems for treatment. Accurate and repetitive measurement of ascites volume during treatment is clinically imperative for effective decisions surrounding treatment continuation. Meanwhile, clinical benefit response in gc, a patient-oriented assessment framework of treatment efficacy, should be used in future clinical trials for malignant ascites caused by gc. Although several treatment options have been reported, further studies are mandatory to develop a solid and optimal treatment strategy.
Publish Date	2015-10-19 09:14
Citation	Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 2015; 21(39): 10936-10947
URL	http://www.wjgnet.com/1007-9327/full/v21/i39/10936.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i39.10936

Full Article (PDF)	WJG-21-10936.pdf
Full Article (Word)	WJG-21-10936.doc
Manuscript File	18550-Review.docx
Answering Reviewers	18550-Answering reviewers.pdf
Audio Core Tip	18550-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18550-Conflict-of-interest statement.pdf
Copyright License Agreement	18550-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18550-Language certificate.pdf
Peer-review Report	18550-Peer-review(s).pdf
Scientific Misconduct Check	18550-Scientific misconduct check.pdf
Scientific Editor Work List	18550-Scientific editor work list.pdf